Ara
Toplam kayıt 6, listelenen: 1-6
Role of 68-Ga-PSMA-PET/CT in pelvic radiotherapy field definitions for lymph node coverage in prostate cancer patients
(2020)
Purpose: To evaluate the distribution of metastatic lymph nodes (LN) detected on Ga-68-PSMA-positron emission tomography/computed tomography (PET/CT) in treatment-naive prostate cancer (PC) patients and to analyze the LN ...
The effect of androgen deprivation therapy on Ga-68-PSMA tracer uptake in non-metastatic prostate cancer patients
(2020)
Purpose To evaluate the effect of neoadjuvant androgen deprivation treatment (ADT) on prostate-specific membrane antigen (PSMA) tracer uptake demonstrated in Ga-68-PSMA-positron emission tomography (PET/CT) in non-metastatic ...
The prognostic value of mean apparent diffusion coefficient measured with diffusion-weighted magnetic resonance image in patients with prostate cancer treated with definitive radiotherapy
(2022)
Purpose: To assess the correlation between initial tumor apparent diffusion coefficient (ADC) values and clinicopathological parameters in prostate cancer (PCa) patients treated with definitive radiotherapy (RT). Additionally, ...
Incidental testicular doses during volumetric-modulated arc radiotherapy in prostate cancer patients
(2020)
Purpose To compare the incidental testicular doses during volumetric-modulated arc therapy (VMAT) in patients receiving prostate-only and pelvic lymphatic irradiation. Materials and methods Testicular doses in 40 intermediate- ...
Prostate Mucinous Carcinoma Treated with Definitive Radiotherapy and Hormonal Therapy: Case Report and Review of the Literature
(2014)
Prostate mucinous carcinoma (MC) is a rare variant of prostate adenocarcinoma that is characterized by large pools of extracellular mucin, which by definition compose at least 25% of the tumor volume.
Prostate MC has 3 ...
Stereotactic radiotherapy to oligoprogressive lesions detected with Ga-68-PSMA-PET/CT in castration-resistant prostate cancer patients
(2021)
Purpose We assessed the outcomes of stereotactic body radiotherapy (SBRT) to treat oligoprogressive castration-resistant prostate cancer (CRPC) patients with <= 5 lesions using gallium prostate-specific membrane antigen-positron ...